Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)

Introduction: Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods: We present the real-life experience of the compassionate use of imipenem/c...

ver descrição completa

Detalhes bibliográficos
Autores: Machuca, I., Domínguez, A., Amaya, R., Arjona, C., Gracia-Ahufinger, I., Carralon, M., Giron, R., Gea, I., Benito, Natividad|||0000-0001-6410-013X, Martin, A., Galan, F., Martinez, Jose Antonio, Iglesias, R., Revuelto, J., Caston, J.J., Cano, Amanda|||0000-0001-9567-4283, Ruiz-Arabi, E., Martínez-Martínez, L., Torre-Cisneros, J.|||0000-0003-1529-6302
Formato: artículo
Fecha de publicación:2025
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:320042
Acesso em linha:https://ddd.uab.cat/record/320042
https://dx.doi.org/urn:doi:10.1007/s40121-024-01077-z
Access Level:acceso abierto
Palavra-chave:Pseudomonas aeruginosa
Carbapenem
Cilastatin
Imipenem
Multidrug
Relebactam
Resistant
Descrição
Resumo:Introduction: Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods: We present the real-life experience of the compassionate use of imipenem/cilastatin/relebactam in a descriptive study involving 14 patients with DTR-P. aeruginosa infection and limited treatment options. Results: The primary source of infection was skin and soft tissue infection, 57.1% (8/14), followed by respiratory infection-pneumonia, 28.6% (4/14). At the onset of infection, 71.4% (10/14) of patients were in the intensive care unit (ICU). All our patients had a Charlson Score of ≥ 3. Septic shock was observed in 64.3% (9/14) of patients. The median treatment duration was 15 days, and no patient experienced an adverse event that required treatment interruption. All-cause 30-day mortality was observed in 42.9% of cases (6/14), while clinical efficacy and microbiological success were observed in 64.3% (9/14). Conclusions: Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.

Registos relacionados